SIGA Technologies, Inc.

NasdaqGM:SIGA Stock Report

Market Cap: US$634.8m

SIGA Technologies Past Earnings Performance

Past criteria checks 5/6

SIGA Technologies's earnings have been declining at an average annual rate of -50.8%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 27.3% per year. SIGA Technologies's return on equity is 34.6%, and it has net margins of 48.6%.

Key information

-50.8%

Earnings growth rate

-48.3%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-27.3%
Return on equity34.6%
Net Margin48.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

Mar 19
Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

Recent updates

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company

Mar 31
SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Mar 25

Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

Mar 19
Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)

Feb 15
The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)

Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?

Jan 13
Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?

SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX

Sep 29

Siga monkeypox therapy undergoes NIH-led late-stage trial

Sep 09

Scientists behind key COVID study run monkeypox trial for SIGA therapy

Aug 23

SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg

Aug 17

Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

Aug 12
Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise

Aug 09

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

Aug 01

SIGA Technologies: Buy Monkeypox

Jul 25

Siga Technologies receives approval from UK for tecovirimat

Jul 08

SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak

May 27

SIGA Technologies: There's An Assured Market For A Smallpox Vaccine

Dec 12

It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year

Jun 08
It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year

SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX

Apr 28

Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years

Feb 22
Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years

We're Not So Sure You Should Rely on SIGA Technologies' (NASDAQ:SIGA) Statutory Earnings

Feb 02
We're Not So Sure You Should Rely on SIGA Technologies' (NASDAQ:SIGA) Statutory Earnings

SIGA Technologies +4% AH, announces Canada contract to purchase up to ~$33M of oral TPOXX

Jan 13

Is SIGA Technologies, Inc.'s (NASDAQ:SIGA) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 12
Is SIGA Technologies, Inc.'s (NASDAQ:SIGA) Latest Stock Performance Being Led By Its Strong Fundamentals?

Read This Before Buying SIGA Technologies, Inc. (NASDAQ:SIGA) Shares

Dec 22
Read This Before Buying SIGA Technologies, Inc. (NASDAQ:SIGA) Shares

Getting In Cheap On SIGA Technologies, Inc. (NASDAQ:SIGA) Is Unlikely

Dec 04
Getting In Cheap On SIGA Technologies, Inc. (NASDAQ:SIGA) Is Unlikely

Revenue & Expenses Breakdown
Beta

How SIGA Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:SIGA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2314068220
30 Sep 2335-5210
30 Jun 239828340
31 Mar 2310933360
31 Dec 2211134350
30 Sep 22215108330
30 Jun 2214772180
31 Mar 2213970180
31 Dec 2113469180
30 Sep 215616180
30 Jun 219544170
31 Mar 2112764150
31 Dec 2012556150
30 Sep 209132140
30 Jun 20556140
31 Mar 2019-18130
31 Dec 1927-7130
30 Sep 192450140
30 Jun 19487439140
31 Mar 19486435130
31 Dec 18477422130
30 Sep 18477359120
30 Jun 187-39120
31 Mar 189-39120
31 Dec 1712-36120
30 Sep 1718-36130
30 Jun 1721-36130
31 Mar 1719-38140
31 Dec 1615-40140
30 Sep 1612-49120
30 Jun 169-46110
31 Mar 168-43100
31 Dec 158-39110
30 Sep 155-38100
30 Jun 155-273120
31 Mar 154-269130
31 Dec 143-265130
30 Sep 143-251140
30 Jun 144-16130
31 Mar 145-16130
31 Dec 136-17130
30 Sep 137-15120
30 Jun 137-14120

Quality Earnings: SIGA has high quality earnings.

Growing Profit Margin: SIGA's current net profit margins (48.6%) are higher than last year (30.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SIGA's earnings have declined by 50.8% per year over the past 5 years.

Accelerating Growth: SIGA's earnings growth over the past year (100.8%) exceeds its 5-year average (-50.8% per year).

Earnings vs Industry: SIGA earnings growth over the past year (100.8%) exceeded the Pharmaceuticals industry -14.6%.


Return on Equity

High ROE: SIGA's Return on Equity (34.6%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.